Prospects for hepatitis C elimination in networks of people who inject drugs through improvements in the care continuum
通过改善护理连续性在注射吸毒者网络中消除丙型肝炎的前景
基本信息
- 批准号:10591937
- 负责人:
- 金额:$ 18.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAntiviral TherapyAttentionAwardBayesian MethodCalibrationCaringCharacteristicsCollaborationsCommunicable DiseasesCommunicationComplexComplicationContinuity of Patient CareEconomicsEffectivenessEffectiveness of InterventionsEnvironmentEvaluationFoundationsGoalsHIVHIV InfectionsHIV/HCVHealthHealth PolicyHepatitis CHepatitis C TherapyHepatitis C TransmissionHepatitis C virusHeterogeneityIndividualInfectionInfrastructureInjecting drug userInjectionsInterventionKnowledgeLeadershipLifeMathematicsMeta-AnalysisMissionModelingMorbidity - disease rateNational Institute of Drug AbuseNeedle-Exchange ProgramsNetwork-basedOutcomePathway interactionsPolicy MakingPopulationPrognosisPublic HealthResearchResearch PersonnelResearch TrainingRiskRouteServicesSex BehaviorStructureTestingTimeTrainingTreatment EfficacyTreatment outcomeTrustUnited States National Institutes of HealthVariantViralWorkcareerco-infectioncollaborative environmentcost effectivecost effectivenessdesigndisabilitydisorder controleffective interventioneffectiveness evaluationefficacy evaluationevidence basehealth economicsimprovedimproved outcomemedical schoolsmodels and simulationnetwork modelsnovelrural areaskill acquisitionskillssocialsocial determinantssocial vulnerabilitysocietal costssystematic reviewtherapy designtransmission processuptakeurban area
项目摘要
Project Summary/Abstract
People who inject drugs (PWID) account for the majority of hepatitis C virus (HCV) infections in the U.S.
Improving the HCV care continuum, with particular attention to the complication of HIV-coinfection, is critical
to achieving HCV elimination. Heterogeneous injection and sexual networks among PWID can significantly
affect HCV and HIV transmission and intervention outcomes. Although empirical studies on the efficacy of
interventions to improve the HCV care continuum in the direct-acting antiviral (DAA) era have begun to
accumulate, there remains a lack of understanding of the population level impact and cost-effectiveness of
these interventions to inform policymaking. My long-term goal is to develop mathematical and statistical
simulation models to inform health policies relating to infectious disease control. The overall objective for
this application, which is a critical step toward attaining my long-term goal, is to develop a dynamic agent-
based network model of HCV and HIV transmission among PWID, to determine the population-level impact
and cost-effectiveness of interventions to improve the HCV care continuum. My central hypothesis is that
interventions that target multiple stages of the care continuum, taking account of individual characteristics,
service environment, and meso/macro-level contexts, will have significant population-level impact in
decreasing HCV and HIV infections and associated complications while being cost-effective. The central
hypothesis will be tested by pursuing three specific aims: 1) Identify social determinants of the HCV care
continuum outcomes among PWID, and effective interventions to improve these outcomes in the DAA era;
2) Determine the population-level impact and cost-effectiveness of different interventions to improve the
HCV care continuum among PWID; 3) Identify the determinants of differences in population-level impact of
interventions to improve the HCV care continuum based on specific features of PWID networks. I will
pursue these aims using systematic review and meta-analysis (Aim 1), expanding our model of HCV
transmission via injection network to incorporate sexual network and HIV transmission (Aim 2), and fitting
the model to different PWID networks and evaluate impact across the networks (Aim 3). To complete the
research and advance my career, I will obtain research training in evidence synthesis, Bayesian methods
for model calibration, and health economics, and professional training in scientific communication,
leadership, and collaboration, in the interdisciplinary environment of the Department of Health Policy at the
Stanford School of Medicine. The expected outcome is a novel model platform to evaluate complex
HIV/HCV intervention strategies for improving the health of PWID. The proposed research is significant
because the results will provide systematic understanding of social determinants of HCV care in PWID and
essential evidence on the population-level impact and cost-effectiveness of interventions to improve the
HCV care continuum in different PWID populations to inform policymaking on HCV elimination.
项目摘要/摘要
在美国,注射毒品者(PWID)是丙型肝炎病毒(HCV)感染的主要原因。
改善丙型肝炎病毒护理连续体,特别注意艾滋病毒合并感染的并发症,是至关重要的。
为实现消除丙型肝炎病毒而努力。PWID之间的异质注射和性网络可以显著
影响丙型肝炎病毒和艾滋病病毒的传播和干预结果。尽管对其疗效的实证研究
在直接作用抗病毒(DAA)时代改善丙型肝炎病毒护理连续体的干预措施已经开始
积累起来,仍然缺乏对人口水平的影响和成本效益的了解
这些干预措施为政策制定提供信息。我的长期目标是发展数学和统计学
模拟模型,为与传染病控制相关的卫生政策提供信息。的总体目标
这个应用程序是实现我的长期目标的关键一步,它是开发一种动态代理-
基于丙型肝炎病毒和艾滋病病毒在PWID中传播的网络模型,以确定人口水平的影响
以及改善丙型肝炎病毒护理连续体的干预措施的成本效益。我的中心假设是
针对护理连续体的多个阶段的干预措施,考虑到个人特点,
服务环境和中/宏观层面的环境将在#年对人口层面产生重大影响
减少丙型肝炎病毒和艾滋病毒感染及相关并发症,同时具有成本效益。中环
假设将通过追求三个具体目标来检验:1)确定丙型肝炎病毒护理的社会决定因素
PWID的连续结果,以及在DAA时代改善这些结果的有效干预措施;
2)确定不同干预措施对人口的影响和成本效益,以改善
PWID中的丙型肝炎病毒护理连续体;3)确定不同人群水平影响的决定因素
根据PWID网络的具体特点改善丙型肝炎病毒护理连续体的干预措施。这就做
使用系统回顾和荟萃分析(目标1)实现这些目标,扩展我们的丙型肝炎病毒模型
通过注射网络传播,将性网络和艾滋病毒传播结合在一起(目标2),并安装
该模型适用于不同的PWID网络,并评估这些网络的影响(目标3)。要完成
研究和发展我的事业,我将获得证据合成,贝叶斯方法方面的研究培训
用于模型校准、卫生经济学和科学交流方面的专业培训,
在卫生政策部的跨学科环境中的领导和协作
斯坦福医学院。预期的结果是一个新的评估复杂的模型平台
改善PWID健康的HIV/丙型肝炎干预策略。这项拟议的研究具有重要意义
因为这些结果将系统地了解PWID和PWID患者中丙型肝炎护理的社会决定因素
关于改善人口状况的干预措施的人口影响和成本效益的基本证据
在不同的PWID人群中提供丙型肝炎病毒护理连续体,为消除丙型肝炎病毒的政策制定提供信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lin Zhu其他文献
Lin Zhu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lin Zhu', 18)}}的其他基金
Linking Social-Behavior Contextual Factors and Allostatic Load to Chronic Diseases in Diverse Asian Americans: A Socioecological Approach to Advancing Precision Medicine and Health Equity
将社会行为背景因素和稳态负荷与不同亚裔美国人的慢性病联系起来:推进精准医疗和健康公平的社会生态学方法
- 批准号:
10799170 - 财政年份:2023
- 资助金额:
$ 18.01万 - 项目类别:
Examining the Integrative Effects of Adolescent, Parent, Provider, and Practice Level Factors on Adolescents' HPV Vaccine Uptake across Six Asian American Subgroups
检查青少年、家长、提供者和实践水平因素对六个亚裔美国人亚群体青少年 HPV 疫苗接种的综合影响
- 批准号:
10371334 - 财政年份:2022
- 资助金额:
$ 18.01万 - 项目类别:
Examining the Integrative Effects of Adolescent, Parent, Provider, and Practice Level Factors on Adolescents' HPV Vaccine Uptake across Six Asian American Subgroups
检查青少年、家长、提供者和实践水平因素对六个亚裔美国人亚群体青少年 HPV 疫苗接种的综合影响
- 批准号:
10551328 - 财政年份:2022
- 资助金额:
$ 18.01万 - 项目类别:
Does Senescence Impair the Cardiovascular Benefits of Menopause Hormone Therapy?
衰老是否会损害更年期激素疗法对心血管的益处?
- 批准号:
10612102 - 财政年份:2022
- 资助金额:
$ 18.01万 - 项目类别:
Does Senescence Impair the Cardiovascular Benefits of Menopause Hormone Therapy?
衰老是否会损害更年期激素疗法对心血管的益处?
- 批准号:
10429132 - 财政年份:2022
- 资助金额:
$ 18.01万 - 项目类别:
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 18.01万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 18.01万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 18.01万 - 项目类别:
Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10683329 - 财政年份:2022
- 资助金额:
$ 18.01万 - 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10481430 - 财政年份:2022
- 资助金额:
$ 18.01万 - 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
- 批准号:
nhmrc : 1196520 - 财政年份:2021
- 资助金额:
$ 18.01万 - 项目类别:
Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10260234 - 财政年份:2021
- 资助金额:
$ 18.01万 - 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10548114 - 财政年份:2021
- 资助金额:
$ 18.01万 - 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
- 批准号:
10400318 - 财政年份:2020
- 资助金额:
$ 18.01万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial)
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)
- 批准号:
449805 - 财政年份:2020
- 资助金额:
$ 18.01万 - 项目类别:
Studentship Programs